ReacX Pharmaceuticals, Inc. (“ReacX” or the “Company”), a company focused on developing and marketing pharmaceutical treatments for addictions, announced the appointment of Patricia Trifunov as Chief Executive Officer. Ms. Trifunov has extensive experience in the commercialization of drugs in the government arena. She has run both federal ($3.5 billion) and state government divisions at GSK for over a dozen years, and then in her own consulting business. She will be first focused on the re-entry of Probuphine back on the market, a six-month implant of buprenorphine that was voluntarily removed from the market following COVID and is FDA-approved for sale
in the US.

As CEO of her own consulting company for sixteen years, Ms. Trifunov focused on building government markets such as Medicaid, the Veterans Administration, Department of Defense, Indian Health Services and the naloxone distribution system in the fifty states. These capabilities make her the ideal fit for our organization as she has spent many of these years specifically focused on the commercialization of products for substance use disorder and the opioid crisis.

“As I take the helm of ReacX, I am ever mindful of the severity of this chronic and deadly illness for which countless lives are lost every year. According to a RAND study more than 40% of Americans know someone who has died of a fatal drug overdose, and over 2.7 million people are estimated to be addicted to opioids. Unfortunately, only one in five of these folks with substance use disorder are on active medications for treatment. New treatments are badly needed, and a once every-six-months buprenorphine implant could revolutionize the patient journey to recovery.”

Ms. Trifunov lives in Sedona, AZ with her husband and has a pharmacy degree from the University of Saskatchewan.

Forward Looking Statements

This communication contains certain “forward-looking statements” within the meaning of the U.S. federal securities laws. Such statements are based upon various facts and derived utilizing numerous important assumptions and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Statements preceded by, followed by or that otherwise include the words “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans” and similar expressions or future or conditional verbs such as “will,” “should,” “would,” “may” and “could” are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. Any forward-looking statement speaks only as of the date on which it was initially made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise, unless required by law.

REACX PHARMACEUTICALS

833-824-0824
dleslie@reacxpharma.com
400 Oyster Point Blvd, #326, San Francisco, CA 94080